Assessment of Interferon-γ Levels and Leishmanin Skin Test Results in Persons Recovered for Leishmaniasis

Overview

Journal Am J Trop Med Hyg

Specialty Tropical Medicine

Date 2012 Jul 6

PMID 22764294

Citations 12

Authors

Mohammad H Alimohammadian

Stephen L Jones

Haideh Darabi

Farhad Riazirad

Soheila Ajdary

Aliakbar Shabani

Mohammad A Rezaee

Mehdi Mohebali

Zohreh Hosseini

Farrokh Modabber

Affiliations

Soon will be listed here.

Abstract

Patients who recover from leishmaniasis usually show development of strong immunity and induction of interferon-γ (IFN-γ) and delayed type hypersensitivity. In a randomized trial, we analyzed the IFN-γ response by using a Quantiferon-Leishmania assay against three Leishmania peptide antigens and compared it with results of the leishmanin skin test (LST) in persons residing in areas in Iran to which zoonotic cutaneous leishmaniasis (ZCL, 181 persons), anthroponotic cutaneous leishmaniasis (ACL, 104 persons), and zoonotic visceral leishmaniasis (ZVL, 67 persons) are endemic. The percentage of persons with an IFN-γ-positive response (> 0.2 IU/mL) to three antigens and the mean concentration of IFN-γ induced by the antigens were higher for persons from areas endemic for ZVL than for persons from areas endemic for ZCL and ACL. The percentage of persons with LST-positive results (≥ 5 mm indurations) was 99%, 94%, and 70% for areas with ZCL, ACL, and ZVL, respectively. Our data indicate that the LST is significantly more sensitive than IFN-γ levels in persons who have been cured of cutaneous leishmaniasis than in persons who have been cured of ZVL.

Citing Articles

Memory T cells: promising biomarkers for evaluating protection and vaccine efficacy against leishmaniasis.

Nateghi-Rostami M, Sohrabi Y Front Immunol. 2024; 15:1304696.

PMID: 38469319 PMC: 10925770. DOI: 10.3389/fimmu.2024.1304696.

A Historic Review of the Role of CD4+ T-Cell Subsets in Development of the Immune Responses against Cutaneous and Visceral Leishmaniases.

Alimohmmadian M, Ajdary S, Bahrami F Iran Biomed J. 2022; 26(2):99-109.

PMID: 35090305 PMC: 8987415. DOI: 10.52547/ibj.26.2.99.

A review of the leishmanin skin test: A neglected test for a neglected disease.

Carstens-Kass J, Paulini K, Lypaczewski P, Matlashewski G PLoS Negl Trop Dis. 2021; 15(7):e0009531.

PMID: 34292942 PMC: 8297750. DOI: 10.1371/journal.pntd.0009531.

Potential biomarkers of immune protection in human leishmaniasis.

Nateghi Rostami M, Khamesipour A Med Microbiol Immunol. 2021; 210(2-3):81-100.

PMID: 33934238 PMC: 8088758. DOI: 10.1007/s00430-021-00703-8.

Whole Blood Stimulation Assay as a Treatment Outcome Monitoring Tool for VL Patients in Ethiopia: A Pilot Evaluation.

Aleka Y, Ibarra-Meneses A, Workineh M, Tajebe F, Kiflie A, Tessema M J Immunol Res. 2020; 2020:8385672.

PMID: 32377538 PMC: 7193677. DOI: 10.1155/2020/8385672.

References

Matos D, Azeredo-Coutinho R, Schubach A, Conceicao-Silva F, Baptista C, Moreira J . Differential interferon- gamma production characterizes the cytokine responses to Leishmania and Mycobacterium leprae antigens in concomitant mucocutaneous leishmaniasis and lepromatous leprosy. Clin Infect Dis. 2005; 40(2):e5-12. DOI: 10.1086/427069. View

Bahar K, Dowlati Y, Shidani B, Alimohammadian M, Khamesipour A, Ehsasi S . Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. Clin Dermatol. 1996; 14(5):489-95. DOI: 10.1016/0738-081x(96)00071-5. View

Launois P, Tacchini-Cottier F, Parra-Lopez C, Louis J . Cytokines in parasitic diseases: the example of cutaneous leishmaniasis. Int Rev Immunol. 1999; 17(1-4):157-80. DOI: 10.3109/08830189809084491. View

Soleimanzadeh G, Edrissian G, Nadim A . Epidemiological aspects of kala-azar in Meshkin-Shahr, Iran: human infection. Bull World Health Organ. 1993; 71(6):759-62. PMC: 2393533. View

Nadim A, Rashti A, Faghih A . Epidemiology of cutaneous leishmaniasis in Iran: B. Khorassan. 3. Human infection. Bull Soc Pathol Exot Filiales. 1969; 62(4):702-10. View

Tashakori M, Mahnaz T, Kuhls K, Katrin K, Al-Jawabreh A, Amer A . Leishmania major: genetic heterogeneity of Iranian isolates by single-strand conformation polymorphism and sequence analysis of ribosomal DNA internal transcribed spacer. Acta Trop. 2006; 98(1):52-8. DOI: 10.1016/j.actatropica.2006.01.010. View

Muller I . Role of T cell subsets during the recall of immunologic memory to Leishmania major. Eur J Immunol. 1992; 22(12):3063-9. DOI: 10.1002/eji.1830221206. View

Ajdary S, Riazi-Rad F, Alimohammadian M, Pakzad S . Immune response to Leishmania antigen in anthroponotic cutaneous leishmaniasis. J Infect. 2009; 59(2):139-43. DOI: 10.1016/j.jinf.2009.05.010. View

Reiner S, Locksley R . The regulation of immunity to Leishmania major. Annu Rev Immunol. 1995; 13:151-77. DOI: 10.1146/annurev.iy.13.040195.001055. View

10.

Kemp M, Hey A, Kurtzhals J, Christensen C, Gaafar A, Mustafa M . Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis. Clin Exp Immunol. 1994; 96(3):410-5. PMC: 1534571. DOI: 10.1111/j.1365-2249.1994.tb06043.x. View

11.

Da-Cruz A, Oliveira-Neto M, Bertho A, Mendes-Aguiar C, Coutinho S . T cells specific to leishmania and other nonrelated microbial antigens can migrate to human leishmaniasis skin lesions. J Invest Dermatol. 2010; 130(5):1329-36. DOI: 10.1038/jid.2009.428. View

12.

Momeni A, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, Ghassemi R . A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine. 1999; 17(5):466-72. DOI: 10.1016/s0264-410x(98)00220-5. View

13.

Murray H, Berman J, Davies C, Saravia N . Advances in leishmaniasis. Lancet. 2005; 366(9496):1561-77. DOI: 10.1016/S0140-6736(05)67629-5. View

14.

Muller I, Fruth U, Louis J . Immunobiology of experimental leishmaniasis. Med Microbiol Immunol. 1992; 181(1):1-12. DOI: 10.1007/BF00193391. View

15.

Sokal J . Editorial: Measurement of delayed skin-test responses. N Engl J Med. 1975; 293(10):501-2. DOI: 10.1056/NEJM197509042931013. View

16.

Wakil A, Wang Z, Ryan J, Fowell D, Locksley R . Interferon gamma derived from CD4(+) T cells is sufficient to mediate T helper cell type 1 development. J Exp Med. 1998; 188(9):1651-6. PMC: 2212510. DOI: 10.1084/jem.188.9.1651. View

17.

Ajdary S, Alimohammadian M, Eslami M, Kemp K, Kharazmi A . Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun. 2000; 68(4):1760-4. PMC: 97345. DOI: 10.1128/IAI.68.4.1760-1764.2000. View

18.

Reithinger R, Dujardin J, Louzir H, Pirmez C, Alexander B, Brooker S . Cutaneous leishmaniasis. Lancet Infect Dis. 2007; 7(9):581-96. DOI: 10.1016/S1473-3099(07)70209-8. View

19.

Turgay N, Balcioglu I, Ozensoy Toz S, Ozbel Y, Jones S . Quantiferon-Leishmania as an epidemiological tool for evaluating the exposure to Leishmania infection. Am J Trop Med Hyg. 2010; 83(4):822-4. PMC: 2946749. DOI: 10.4269/ajtmh.2010.09-0605. View

20.

Nateghi Rostami M, Keshavarz H, Edalat R, Sarrafnejad A, Shahrestani T, Mahboudi F . CD8+ T cells as a source of IFN-γ production in human cutaneous leishmaniasis. PLoS Negl Trop Dis. 2010; 4(10):e845. PMC: 2953482. DOI: 10.1371/journal.pntd.0000845. View